A股異動 | 通威股份(600438.SH)漲近5% 簽訂重大銷售框架合同
格隆匯11月9日丨通威股份(600438.SH)現報32.07元,漲4.8%,暫成交26億元,最新總市值1375億元。通威股份上週五(6日)晚間發公告稱,公司下屬永祥多晶硅等子公司擬與晶科能源及其子公司四川晶科簽訂2020-2023年的《多晶硅購銷框架協議》。合同約定2020年11月-2023年12月期間,晶科能源及四川晶科向通威股份下屬永祥多晶硅、永祥新能源、內蒙通威、雲南通威合計採購多晶硅9.3萬噸。按照當前市場價格及公司目前成本水平測算,預計本次合同約定的多晶硅銷售量將產生淨利潤合計約25億元。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.